Claremont Graduate University

Dr. Susan Love Foundation to transfer data and findings to continue the work on breast cancer research and other women's health issues. LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The 6-year Health of Women (HOW) Study was a first-of-its kind international online study to better understand breast cancer and its underlying cause. The HOW Study® asked health-related questions on topics like family history, reproductive health, diet, and exercise. Over the course of the study, more than 65,000 women participated to help identify how family history, reproductive health, diet and exercise contribute to the cause of breast cancer. Preliminary results from the HOW Study revealed a critical need to address issues often overlooked among those living with metastatic breast cancer (MBC). While industry partners develop treatments that will keep people alive longer, the MBCCD project set out to help them live better. This project documented a full range of collateral damage experienced by those living with MBC and is currently developing a set of recommendations aimed at improving quality of life. Dr. Jessica Clague DeHart is a molecular cancer epidemiologist, Associate Professor at Claremont Graduate University, and the CEO/Founder of LYTE Foundation. Dr. Clague DeHart has a long history of working with breast cancer advocates and oversees a translational research team focused on comprehensively meeting the needs of the growing and diverse breast cancer community through epidemiologic and interventional investigation, and community-based implementation. Dr. Clague DeHart believes "even the most effective intervention is meaningless if no one will do it." Thus, a major goal of her research is to develop community-based interventions that are not only biologically effective in preventing disease and the collateral damage of treatment, but also feasible for the average person to maintain. The HOW Study and MBCCD project have and will continue to be major catalysts in achieving this goal. Dr. Clague DeHart also serves on the scientific advisory board of the Dr. Susan Love Foundation for Breast Cancer Research, where she advises on the Love Research Army and conducts research based on data from the HOW Study, MBCCD project and other programs. The transfer of the HOW Study and MBCCD project data and research from the Foundation to Dr. Clague DeHart will further her and her team's impactful research for years to come. "I am honored and humbled to continue this incredible work and to ensure Dr. Susan Love's research legacy lives on," shared Dr. Clague DeHart. About Dr. Susan Love Foundation for Breast Cancer Research Dr. Susan Love Foundation for Breast Cancer Research challenges the status quo to end breast cancer and improve the lives of those impacted by it through education and advocacy. The Foundation drives collaborative, cutting-edge research with nontraditional partners, brings to light the collateral damage of treatment and seeks ways to diminish it, and interprets science to empower patients. Fast, flexible, and project-based, the Foundation actively engages the public in scientific research to ensure that it produces accurate and meaningful results. For more information please visit: DrSusanLoveResearch.org For Media Inquiries: Christopher Clinton Conway CEO, Dr. Susan Love Foundation for Breast Cancer Research [email protected] 310-562-7912 SOURCE Dr. Susan Love Foundation for Breast Cancer Research

Previously served as senior economic advisor to the Commissioner of the Food and Drug Administration and to the Administrator of the Centers for Medicare and Medicaid Services IRVINE, Calif., Nov. 29, 2022 /PRNewswire/ -- GATC Health ("GATC" or "the Company"), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that Tomas J. Philipson has joined its Medical Advisory Board. Dr. Philipson was a member of the White House Council of Economic Advisers from 2017 to 2019 and it's chairman from 2019 to 2020, leading a group of economists who advise the President on a wide range of policy issues. Dr. Philipson previously served in the public sector as the senior economic advisor to the FDA Commissioner of the Food and Drug Administration (FDA), as well as to the Administrator of the Centers for Medicare and Medicaid Services (CMS) during the second Bush Administration. Dr. Philipson is currently Co-Director of the Center for Choice in the Department of Economics at the University of Chicago. With decades of economic, healthcare and government leadership, Dr. Philipson will be a valued liaison for the Company to major pharmaceutical, healthcare and regulatory entities. "I believe this platform is an extraordinarily powerful tool for firms investing in biopharma," Dr. Tomas Philipsom Dr. Philipson co-founded Precision Health Economics, a premium brand health care consultancy which served global Fortune 500 healthcare clients on a range of commercial and policy issues. Dr. Philipson also served as a healthcare advisor to Senator John McCain's 2008 presidential campaign and as a scientific advisor to the House of Representatives on the 21st Century Cures legislation and served on the steering committee of then-Vice President Biden's Cancer Moon Shot Initiative. "GATC Health's AI platform has unrivalled potential to transform the economics of drug discovery," said Dr. Philipson. "I believe this platform is an extraordinarily powerful tool for firms investing in biopharma by identifying a drug candidate's success or failure early in the clinical trial process—potentially saving hundreds of millions per drug. A recent validation study proved GATC's ability to identify drug candidates' clinical trial success with 88% accuracy and identify a future failure with 84% accuracy. This is an 1,100% improvement over the current industry standard. I look forward to sharing GATC's capabiltites to help other cutting-edge biotech companies grow and advance their mission. Dr. Philipson serves as a research associate at the National Bureau of Economic Research as well as an advisor for Biologx, PragmaHealth, Liberatio and Epigenetix. Additionally, he had a standing op-ed column at Forbes and frequently is featured in numerous popular media outlets such as CNN, NBC, FOX News, The New York Times, The Wall Street Journal and The Washington Post, among others. Dr. Philipson has held Visiting Fellow and Senior Fellow positions at American Enterprise Institute and the Milken Institute, respectively. He has received numerous worldwide research awards and is a two-time winner of the highest award in his field, the Arrow Award of The International Health Economics Association. "We are delighted to welcome Dr. Philipson to GATC Health's Advisory Board," said Jeff Moses, President of GATC Health. "His impressive career in serving as a leader, professor and advisor in both economics and healthcare makes Dr. Philipson an invaluable and trusted resource for GATC, as we establish key partnerships and explore the many ways our novel AI platform can improve the health and lives of people around the world." Dr. Philipson received his MA and PhD in economics from the Wharton School at the University of Pennsylvania. He received a BA in mathematics from Uppsala University in Sweden and his MA in Mathematics from Claremont Graduate School in California. About GATC Health GATC Health Corp is a science and technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry's billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed, and every person's unique biology is treated with precision. GATC is accelerating the future of predictive, individualized medicine, today.